FindTrial
Sign In

Role of rTMS and qEEG IN SCHIZOPHRENIA

rTMS and its effect on qEEG in patients with schizophrenia with auditory hallucinations - rTMS,cTBS, qEEG, Schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/02/007948
Enrollment
45
Registered
2017-02-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Schizophrenia

Interventions

Intervention1: cTBS & qEEG on 30 patients with schizophrenia: cTBS 10 sessions, and simulateneously qEEG ON DAY 0, 1 and day 14. Control Intervention1: 15 healthy control: baseline qEEG

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Diagnosis of schizophrenia (F20.0-F20.9) according to Diagnostic Criteria for Research (DCR) of International classification of diseases-tenth edition (ICD-10; World Health Organization, 1992). 2.Patients should be on stable antipsychotic doses. 3.patients given written informed consent.

Exclusion criteria

Exclusion criteria: 1. Current neurological or any co-morbid physical disorder 2. History of substance abuse (Except nicotine and caffeine in past one month) 3. History of epilepsy, significant head injury or any neurosurgical procedure 4. Subjects with cardiac pacemakers or other metal parts in the body 5. Subjects who have received ECT in past 6 months.

Design outcomes

Primary

MeasureTime frame
PSYRATS, PANSS and WHO DAS-2 ScoresTimepoint: Baseline, 2 WEEK & 4 WEEK—

Secondary

MeasureTime frame
Changes in wave frequencies(qEEG) viz., alpha, beta, theta, delta & gammaTimepoint: Base line, day-2 (after 1st cTBS) & DAY 14—

Countries

India

Contacts

Public ContactDr Nishant Goyal

CENTRAL INSTITUTE OF PSYCHIATRY, RANCHI

psynishant@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026